Related Experiment Video
Updated: Aug 22, 2026

Quantifying Tissue-Specific Proteostatic Decline in Caenorhabditis elegans
Published on: September 7, 2021
Integrative transcriptomic and experimental analyses prioritize TPT1 as a PANoptosis-associated candidate molecular
Shijie Dong1, Min Wang2, Chen Liang1
1Department of Neurology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background:
Sarcopenia lacks sensitive molecular markers for early detection, and its relationship with integrated inflammatory cell-death programs remains unclear. PANoptosis integrates apoptotic, pyroptotic, and necroptotic signaling and therefore provides a plausible framework for investigating inflammatory-stress remodeling in aging skeletal muscle.
Methods:
We integrated four bulk-transcriptomic datasets from the Gene Expression Omnibus into a training cohort (66 controls; 37 sarcopenia) and used GSE111016 as an external validation cohort (20 controls; 20 sarcopenia). We intersected differentially expressed genes with a curated PANoptosis-associated gene set and then performed enrichment analysis; least absolute shrinkage and selection operator (LASSO), random forest and extreme gradient boosting (XGBoost) feature selection; nomogram and receiver operating characteristic (ROC) analyses; CIBERSORT immune-cell deconvolution; and single-nucleus RNA sequencing (snRNA-seq) reanalysis. We assessed tumor protein, translationally controlled 1 (TPT1) expression in D-galactose-treated mouse and C2C12 models.
Results:
Among 608 differentially expressed genes, 47 overlapped with the curated PANoptosis-associated gene set. These genes were enriched in apoptotic signaling; cytokine, nuclear factor kappa B (NF-κB), tumor necrosis factor (TNF), and nucleotide-binding oligomerization domain (NOD)-like receptor pathways; regulated necrosis; extracellular-matrix remodeling; and impaired oxidative phosphorylation. Three machine-learning algorithms converged on neurotrophic receptor tyrosine kinase 1 (NTRK1), TPT1, and TNF receptor-associated protein 1 (TRAP1). TPT1 showed the strongest single-gene discrimination, with areas under the ROC curve of 0.819 (95% confidence interval [CI], 0.737-0.900) in the training cohort and 0.753 (95% CI, 0.598-0.907) in the external cohort. Immune-cell deconvolution linked the candidate genes to estimated mast-cell, plasma-cell, cluster of differentiation 8-positive (CD8+) T-cell, and macrophage proportions. Single-nucleus analysis of 97,154 nuclei from 17 donors showed broad TPT1 expression across myonuclear, satellite-cell, stromal, endothelial, and immune compartments, with lower expression in older muscle. Network and gene set variation analyses associated lower TPT1 expression with inflammatory, oxidative-stress, cell-death, and stress-adaptive pathways. In D-galactose-treated mice and C2C12 myotubes, muscle-wasting or senescence-like changes coincided with lower TPT1 protein abundance.
Conclusion:
This study prioritizes TPT1 as a candidate molecular marker associated with the bulk-transcriptomic sarcopenia phenotype. The aging-muscle and D-galactose analyses provide biological context but do not establish sarcopenia specificity or causality. Prospective clinical validation and functional perturbation studies are required.
Insights
Tumor protein, translationally controlled 1 (TPT1) is a potential molecular marker for early sarcopenia detection. Lower TPT1 levels correlate with aging muscle, inflammation, and cell-death pathways, suggesting its role in sarcopenia pathogenesis.
Area of Science:
- Gerontology
- Molecular Biology
- Immunology
Background:
- Sarcopenia lacks sensitive molecular markers for early detection.
- The role of integrated inflammatory cell-death programs in sarcopenia is unclear.
- PANoptosis, integrating apoptosis, pyroptosis, and necroptosis, offers a framework to study aging skeletal muscle.
Purpose of the Study:
- To identify molecular markers for early sarcopenia detection.
- To investigate the association between PANoptosis and sarcopenia.
- To explore the role of TPT1 in aging skeletal muscle.
Main Methods:
- Integrated four bulk-transcriptomic datasets and validated with an external cohort.
- Performed gene set enrichment analysis, machine learning feature selection (LASSO, random forest, XGBoost), nomogram, and ROC analyses.
- Conducted CIBERSORT immune-cell deconvolution, snRNA-seq, and assessed TPT1 expression in mouse and cell models.
Main Results:
- Identified 47 overlapping genes between differentially expressed genes and PANoptosis-associated genes, enriched in inflammatory and cell-death pathways.
- Machine learning algorithms identified NTRK1, TPT1, and TRAP1 as key discriminators, with TPT1 showing strong diagnostic potential (AUC > 0.75).
- Lower TPT1 expression in aging muscle correlated with inflammatory, oxidative stress, and cell-death pathways; reduced TPT1 protein was observed in muscle-wasting models.
Conclusions:
- TPT1 is a promising candidate molecular marker for sarcopenia.
- The study provides biological context for TPT1's role in aging muscle but requires further validation.
- Prospective clinical studies are needed to confirm TPT1's specificity and causality in sarcopenia.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway